Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a synovial biopsy mechanism study of NNC0109-0012 versus adalimumab in rheumatoid arthritis with inadequate methotrexate response
2013-001492-20Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fletikumab in rheumatoid arthritis (RA) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in total histopathological synovitis score. Started Oct 2013; status: terminated.
02
Drugs
fletikumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-001492-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001492-20.